Need extra support quickly? We are working with clients around the world right now to help them tackle new challenges from COVID-19. How can we help you? Learn More >

Orphan Drug Designation (ODD) Submissions

Getting an orphan designation from the Food and Drug Administration (FDA) can be a challenge, and just the designation is not enough. You must get and translate that knowledge into regulatory and drug development efforts to really make a difference.

ProPharma Group will thoroughly evaluate and examine all relevant documents, including product information, scientific articles, public-domain information, disease prevalence data, etc., in order to identify whether or not your drug qualifies as an orphan. If we recommend proceeding with an Orphan Drug Designation (ODD) application, we will build upon the information we obtained to develop and submit the application on your behalf to the FDA’s Office of Orphan Product Development (OOPD). If your orphan drug application is approved, your product will enjoy:

  • Seven years of marketing exclusivity
  • Protocol assistance
  • Tax credits covering up to 50% of clinical trial costs
  • Research grants to help fund clinical investigations for orphan products
  • Waiver of the Prescription Drug User Fee Act (PDUFA) application fee
Contact Us


Need Help Navigating the Dynamic Regulatory Market to Bring Your Product Concept to Market?

Contact us to discover how 30+ years of regulatory experience using a strategic and scientific approach can deliver successful and expeditious outcomes.

Interested in gaining an industry edge? Let us help you stay current.


All fields are required.